Loading...

CEL-SCI Corporation

CVM•AMEX
Healthcare
Biotechnology
$3.82
$1.02(36.43%)

CEL-SCI Corporation (CVM) Stock Overview

Explore CEL-SCI Corporation’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 63.8/100

Key Financials

Market Cap19.5M
P/E Ratio-14.81
EPS (TTM)$-12.30
ROE-0.01%
Fundamental Analysis

AI Price Forecasts

1 Week$3.92
1 Month$2.03
3 Months$0.48
1 Year Target$0.13

CVM Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of CEL-SCI Corporation (CVM) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 72.05, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $0.13.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -14.81 and a market capitalization of 19.5M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

72.05RSI (14)
0.22MACD
20.85ADX
Revenue Growth
0.00%
Profit Growth
$-0.24
↑ 16.82%
EPS Growth
$-0.24
↑ 30.14%
Operating Margin
0.00%
↑ 16.28%
ROE
-1.00%
↑ 16.82%
Dividend Yield
0.00%
Analyst Recommendations data is not available for CVMAnalyst Recommendations details for CVM are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

CEO

Geert R. Kersten

Employees

43

Headquarters

8229 Boone Boulevard, Vienna, VA

Founded

1983

Frequently Asked Questions

;